The Durnell ruling ends the main path for Roundup cancer lawsuits: claims that the label should have warned about cancer. Pending cases can move ahead only on different legal theories, such as design defect, negligence or fraud.
Cornell LII's copy of the Supreme Court opinion records the June 25, 2026 decision. FIFRA is the federal pesticide-labeling law at the heart of the decision. The practical question now is which surviving claim, if any, fits the facts of your case.
Official resources:
- Read the official notice from Cornell — Use this primary source to verify the official announcement.
- Read the official notice from Lawbc — Use this primary source to verify the official announcement.
Table of Contents
- Why warning claims are blocked
- Which claims can still move forward?
- What did the first post-Durnell trial show?
- What should you do about a pending claim?
Why warning claims are blocked
The Court held the federal law expressly preempts state failure-to-warn claims that would require a cancer warning on Roundup's label. A state jury cannot demand what federal regulators rejected for the approved label.
The Cornell LII syllabus ties that result to EPA's repeated findings that glyphosate is not likely to cause cancer. EPA approved Roundup's label without a cancer warning, and makers must use the approved wording unless EPA allows a change.
Which claims can still move forward?
Durnell did not decide design-defect, negligence and fraud theories. Pending plaintiffs can continue only on those non-warning claims, without arguing that a missing cancer warning caused the injury.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
That distinction changes the proof. A design-defect case focuses on the product itself, while fraud and negligence focus on what the company did apart from the label, according to Bergeson and Campbell's analysis of the first post-Durnell trial.
What did the first post-Durnell trial show?
On Oct. 29, 2026, a St. Louis jury returned a unanimous defense verdict for Monsanto in Theresa Aretino et al. v.
Monsanto. The jury rejected design-defect, fraud and negligence claims by three women with non-Hodgkin lymphoma. Insurance Journal reporting Reuters gave the verdict in its report on the Aretino verdict. The same Insurance Journal report says about 65,000 Roundup-related cancer claims remained pending in late October 2026 while Bayer pursued a broader settlement. The Aretino result does not decide those cases, but it shows non-warning theories are harder to win.
What should you do about a pending claim?
Bayer expects a Missouri court to rule before Christmas 2026 on a proposed $7.25 billion Roundup settlement covering tens of thousands of claims. Claims cannot be paid unless the court finally approves it, according to Global Agriculture's settlement timing report.
If you filed or plan to file, take three checks now: Approval is the gate. Ask your lawyer how that court-approval requirement affects your deadline and options.
- Ask your lawyer which theory your case now uses.
- Keep medical and purchase records together.
- Do not assume a payout before court approval.
You Might Also Like
- 3M $7.35 Billion Settlement: What It Means for PFAS Lawsuit Claims
- Suboxone Tooth Decay Lawsuit: What the New Trial Date Means
- Monsanto Roundup Lawsuit: What the November 2026 Settlement Update Means